A detailed history of Creative Planning transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Creative Planning holds 10,858 shares of RVNC stock, worth $27,905. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,858
Holding current value
$27,905
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 11, 2024

BUY
$2.57 - $2.57 $27,905 - $27,905
10,858 New
10,858 $27,000
Q1 2024

May 10, 2024

BUY
$4.65 - $9.31 $53,712 - $107,539
11,551 New
11,551 $56,000
Q1 2023

May 15, 2023

BUY
$18.36 - $35.27 $973 - $1,869
53 New
53 $1,000
Q4 2021

Feb 11, 2022

SELL
$12.46 - $27.87 $113,547 - $253,979
-9,113 Closed
0 $0
Q2 2021

Aug 04, 2021

SELL
$26.8 - $31.84 $616 - $732
-23 Reduced 0.25%
9,113 $270,000
Q1 2021

Apr 30, 2021

BUY
$24.03 - $29.97 $219,538 - $273,805
9,136 New
9,136 $255,000

Others Institutions Holding RVNC

About Revance Therapeutics, Inc.


  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Creative Planning Portfolio

Follow Creative Planning and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.